Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal

Official Title

Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status

Brief Summary

      SchistoVAN aims to study the role of schistosomiasis infection in the modulation of the
      immune response of children to childhood vaccine antigens, as well as the impact of this
      infection on their nutritional status and their haemoglobinaemia.

Detailed Description

      SchistoVAN aims to study the interactions between chronic parasite infections such as
      schistosomiasis and the immunological and nutritional status of children. In this scope, the
      investigators conducted a case-control study where one group of children is infected with
      schistosoma haematobium and the other is not infected with this parasite.

      The investigators then stimulated whole blood of these children with various vaccine antigens
      to address their immune function and study the influence of schistosomiasis infectious state
      on their overall immune condition.

      Aims of the study:

      To evaluate the interaction between schistosomiasis and the nutritional status of children
      and their haemoglobinemia.

      To evaluate the influence of schistosomiasis on children's specific immune response towards
      EPI vaccine antigens, the inflammatory status of children and nutritional serologic markers.

      To compare schistosomiasis diagnostic tools (evaluation of circulating cathodic antigen (CCA)
      strip for diagnosis of urinary schistosomiasis in comparison with microscopy and urinary

      To study prevalence of intestinal parasites such as Blastocystis hominis

Study Type




Study Arms / Comparison Groups

 Infected by Schistosoma haematobium


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

October 2011

Completion Date

October 2011

Primary Completion Date

October 2011

Eligibility Criteria

        Inclusion Criteria:

          -  Members of AnoPalAnoVac cohort

          -  Age: between 6 and 10 years

        Exclusion Criteria:

          -  body temperature > 38.5 ºC

          -  malaria episode




6 Years - 10 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Emmanuel Hermann, PhD A.Pr., , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Biomedical Research Center EPLS


 Institut Pasteur de Lille

Study Sponsor

Emmanuel Hermann, PhD A.Pr., Study Chair, Biomedical Research Center EPLS

Verification Date

March 2012